HK1210042A1 - 包含氫嗎啡酮和納洛酮的藥物組合物 - Google Patents

包含氫嗎啡酮和納洛酮的藥物組合物

Info

Publication number
HK1210042A1
HK1210042A1 HK15110909.2A HK15110909A HK1210042A1 HK 1210042 A1 HK1210042 A1 HK 1210042A1 HK 15110909 A HK15110909 A HK 15110909A HK 1210042 A1 HK1210042 A1 HK 1210042A1
Authority
HK
Hong Kong
Prior art keywords
hydromorphone
naloxone
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
HK15110909.2A
Other languages
English (en)
Inventor
里卡多．阿爾貝托．瓦爾加斯林孔
Original Assignee
Purdue Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50679506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1210042(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Purdue Pharma filed Critical Purdue Pharma
Publication of HK1210042A1 publication Critical patent/HK1210042A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
HK15110909.2A 2012-11-09 2015-11-05 包含氫嗎啡酮和納洛酮的藥物組合物 HK1210042A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261796390P 2012-11-09 2012-11-09
CA2795324A CA2795324C (en) 2012-11-09 2012-11-09 Pharmaceutical compositions comprising hydromorphone and naloxone
PCT/CA2013/000932 WO2014071499A1 (en) 2012-11-09 2013-11-06 Pharmaceutical compositions comprising hydromorphone and naloxone

Publications (1)

Publication Number Publication Date
HK1210042A1 true HK1210042A1 (zh) 2016-04-15

Family

ID=50679506

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15110909.2A HK1210042A1 (zh) 2012-11-09 2015-11-05 包含氫嗎啡酮和納洛酮的藥物組合物

Country Status (13)

Country Link
US (2) US20150283091A1 (zh)
JP (2) JP6359022B2 (zh)
KR (1) KR101774676B1 (zh)
CN (1) CN104902880B (zh)
AU (1) AU2013344281B2 (zh)
BR (1) BR112015009871A2 (zh)
CA (2) CA2795324C (zh)
HK (1) HK1210042A1 (zh)
MX (1) MX363142B (zh)
PH (1) PH12015501015A1 (zh)
SA (1) SA515360408B1 (zh)
SG (1) SG11201502752VA (zh)
WO (1) WO2014071499A1 (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011141490A1 (en) 2010-05-10 2011-11-17 Euro-Celtique S.A. Combination of active loaded granules with additional actives
MX340188B (es) 2010-05-10 2016-06-30 Euro-Celtique S A * Elaboracion de granulos sin activos y tabletas que comprenden los mismos.
AU2014350135B2 (en) 2013-11-13 2017-08-31 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
CA2847781C (en) * 2014-03-28 2019-03-12 Purdue Pharma Reducing drug liking in a subject
US10617686B2 (en) 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10722510B2 (en) 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US9642848B2 (en) 2014-07-08 2017-05-09 Insys Development Company, Inc. Sublingual naloxone spray
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
JP7114570B2 (ja) * 2016-08-17 2022-08-08 ヒクマ・ファーマシューティカルズ・ユー・エス・エイ・インコーポレイテッド 液体ナロキソンスプレー
CN108186599A (zh) * 2018-03-05 2018-06-22 上海祺宇生物科技有限公司 一种高隔氧率的羟丙甲基纤维素空心胶囊及其制备方法
CN114144224A (zh) 2019-03-26 2022-03-04 保科特纳洛克斯恩公司 药物合成物输送器械和方法
WO2020198327A1 (en) * 2019-03-26 2020-10-01 Pocket Naloxone Corp. Devices and methods for delivering pharmaceutical compositions
WO2022101408A1 (en) * 2020-11-13 2022-05-19 Ferrer Internacional, S.A. Synthesis of hydromorphone base
US11278709B1 (en) 2021-03-12 2022-03-22 Pocket Naloxone Corp. Drug delivery device and methods for using same

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866154A (en) * 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
PL190293B1 (pl) * 1997-02-14 2005-11-30 Goedecke Ag Sposób stabilizowania naloksonu i jego soli, stały półstały lub ciekły lek, zawierający nalokson i jego sole oraz zastosowanie środków stabilizujących do zapobiegania dimeryzacji naloksonu
EP0913152B1 (de) * 1997-11-03 2001-12-19 Stada Arzneimittel Ag Stabilisiertes Kombinationsarzneimittel enthaltend Naloxone und ein Opiatanalgetikum
TWI223598B (en) * 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
US6071952A (en) * 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
JP4683842B2 (ja) * 2002-03-14 2011-05-18 ユーロ−セルティーク エス．エイ． 塩酸ナルトレキソン組成物
SI1578350T1 (sl) * 2002-03-26 2009-10-31 Euro Celtique Sa Z gelom obloženi sestavki z zadržanim sproščanjem
JP2006076971A (ja) * 2004-09-13 2006-03-23 Basf Ag 口腔内崩壊錠
EA015615B1 (ru) * 2005-01-28 2011-10-31 Еуро-Селтик С.А. Устойчивые к спиртам лекарственные формы
AU2006251213A1 (en) * 2005-05-25 2006-11-30 Janssen Pharmaceutica N.V. Pediatric formulation of topiramate
PT2057984E (pt) * 2007-11-09 2010-03-10 Acino Pharma Ag Comprimidos retard com hidromorfona
AU2009292631A1 (en) * 2008-09-16 2010-03-25 Nektar Therapeutics Pegylated opioids with low potential for abuse
GB0909680D0 (en) * 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
JP2012533586A (ja) * 2009-07-22 2012-12-27 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 酸化安定化された不正使用防止剤形
US20110150989A1 (en) * 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
US8597681B2 (en) * 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
WO2011141490A1 (en) * 2010-05-10 2011-11-17 Euro-Celtique S.A. Combination of active loaded granules with additional actives
SE1251371A1 (sv) * 2010-05-10 2012-12-27 Euro Celtique Sa Farmaceutiska kompositioner innefattande hydromorfon och naloxon
AU2012320496C1 (en) * 2011-10-06 2017-09-28 Grünenthal GmbH Tamper-resistant oral pharmaceutical dosage form comprising opioid agonist and opioid antagonist

Also Published As

Publication number Publication date
KR20150085825A (ko) 2015-07-24
AU2013344281A1 (en) 2015-05-07
CN104902880A (zh) 2015-09-09
SG11201502752VA (en) 2015-05-28
MX363142B (es) 2019-03-12
US20150283091A1 (en) 2015-10-08
AU2013344281B2 (en) 2016-07-28
US20190224130A1 (en) 2019-07-25
CN104902880B (zh) 2017-08-11
KR101774676B1 (ko) 2017-09-04
BR112015009871A2 (pt) 2017-07-11
PH12015501015B1 (en) 2015-07-27
SA515360408B1 (ar) 2017-04-03
JP2017149725A (ja) 2017-08-31
MX2015005534A (es) 2016-06-02
JP6359022B2 (ja) 2018-07-18
CA2795324A1 (en) 2014-05-09
JP2015536956A (ja) 2015-12-24
CA2881144A1 (en) 2014-05-09
CA2795324C (en) 2015-07-14
PH12015501015A1 (en) 2015-07-27
WO2014071499A1 (en) 2014-05-15

Similar Documents

Publication Publication Date Title
IL274988A (en) Carbamoylpyridone-polycyclic compounds and their pharmaceutical use
HK1210042A1 (zh) 包含氫嗎啡酮和納洛酮的藥物組合物
IL252566B (en) Pharmacy preparations and methods
IL236024A (en) The history of benzimidazole-proline and its pharmaceutical preparations
IL234628A0 (en) Imidazolyl-pyrimidines are converted into amino-indolyl and their use as drugs
IL239369A0 (en) Pyrocyclic morphines and their use
AP3441A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
HK1203050A1 (zh) 新的劑量和製劑
EP2940008A4 (en) Novel benzazepine derivative and pharmaceutical use thereof
GB201208315D0 (en) Pharmaceutical methods and compositions
IL234614B (en) Pharmaceutical composition and preparation method thereof
GB201207064D0 (en) Pharmaceutical compositions comprising 15-hetre and methods of using the same
GB201301179D0 (en) Pharmaceutical composition comprising opioid analgesic

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20211111